<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vulcan Two Group Plc — News on 6ix</title>
<link>https://6ix.com/company/vulcan-two-group-plc</link>
<description>Latest news and press releases for Vulcan Two Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 21 May 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vulcan-two-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d58b50beedb30cb6f8d899.webp</url>
<title>Vulcan Two Group Plc</title>
<link>https://6ix.com/company/vulcan-two-group-plc</link>
</image>
<item>
<title>Results for the period ended 31 December 2025</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/results-for-the-period-ended-31-december-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/results-for-the-period-ended-31-december-2025-3</guid>
<pubDate>Thu, 21 May 2026 06:00:00 GMT</pubDate>
<description>Vulcan Two Group plc reported a pre-tax loss of £1.22 million for the period ending December 31, 2025, during which it operated as a cash shell following a £12 million AIM IPO in September 2025, ending the period with £9.55 million in cash. Significant progress has been made since year-end, including a £40 million institutional placing in March 2026 and the transformational acquisition of three ePharmacy businesses, CloudRx, Webmed, and Hyperdrug, for up to approximately £41.7 million. These acq</description>
</item>
<item>
<title>Notice of Results and Investor Presentation</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/notice-of-results-and-investor-presentation-198</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/notice-of-results-and-investor-presentation-198</guid>
<pubDate>Mon, 18 May 2026 06:00:00 GMT</pubDate>
<description>Vulcan Two Group plc will release its Full Year Results on Thursday, May 21, 2026, and will host a live investor presentation at 12:30pm BST via the Investor Meet Company platform. The management team will discuss the company's vision, buy-and-build strategy, and the growth opportunities in the UK ePharmacy market. The company is focused on becoming the UK's leading regulated ePharmacy platform, having recently acquired CloudRx, Webmed, and Hyperdrug, establishing a diversified and profitable bu</description>
</item>
<item>
<title>Legal Proceedings</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/legal-proceedings-6</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/legal-proceedings-6</guid>
<pubDate>Tue, 05 May 2026 06:00:00 GMT</pubDate>
<description>Vulcan Two Group PLC has been notified that Chrystal Capital Partners LLP has initiated legal proceedings seeking approximately £600,000 in fees related to a prior engagement with the Company's subsidiary. Vulcan Two Group PLC, having received legal advice, considers the claim to be baseless and intends to seek its dismissal, expecting no material commitment of time from directors or distraction from the Company's strategy.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/holdings-in-company-1372</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/holdings-in-company-1372</guid>
<pubDate>Wed, 22 Apr 2026 15:37:00 GMT</pubDate>
<description>Octopus Investments Limited has increased its holding in Vulcan Two Group PLC, crossing a notification threshold on April 21, 2026. The firm now holds 14.16% of the voting rights, representing 3,862,335 shares, up from a previous notification of 13.64%. This acquisition of voting rights was made through Octopus Capital Limited, which effectively holds the same percentage. No financial instruments were involved in this change.
Disclaimer*</description>
</item>
<item>
<title>Completion of Acquisitions and Re-Admission</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/completion-of-acquisitions-and-re-admission</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/completion-of-acquisitions-and-re-admission</guid>
<pubDate>Thu, 19 Mar 2026 08:12:00 GMT</pubDate>
<description>Vulcan Two Group plc has successfully completed the acquisition of CloudRx, Hyperdrug, and Webmed, and has raised £40 million through an institutional Placing. Following shareholder approval, the company's Ordinary Shares were re-admitted to trading on AIM this morning. The total issued share capital now stands at 27,275,000 Ordinary Shares, and Keith Butcher has joined the Board of Directors.
Disclaimer*</description>
</item>
<item>
<title>Result of General Meeting</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/result-of-general-meeting-395</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/result-of-general-meeting-395</guid>
<pubDate>Tue, 17 Mar 2026 10:55:00 GMT</pubDate>
<description>Vulcan Two Group plc announced that all three resolutions presented at its General Meeting on March 17, 2026, were passed unanimously, including the approval of proposed acquisitions, authorization for directors to allot equity securities, and the disapplication of pre-emption rights. Following these approvals, the company expects VCT Admission and commencement of dealings in VCT Placing Shares on AIM at 8:00 a.m. on March 18, 2026, with readmission of the enlarged share capital, totaling 27,275</description>
</item>
<item>
<title>ERP License Agreement Signed</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/erp-license-agreement-signed</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/erp-license-agreement-signed</guid>
<pubDate>Wed, 11 Mar 2026 07:00:00 GMT</pubDate>
<description>Vulcan Two Group plc has signed a five-year license agreement for a central enterprise resource planning (ERP) system, a key component for its ePharmacy growth strategy. The agreement follows a £40 million conditional fundraising and involves an annual subscription fee starting at £80,000, increasing to £100,000 over the term. An implementation fee of approximately £765,000 is expected in 2026, with most of this development expenditure to be capitalised as an intangible asset. This ERP system ai</description>
</item>
<item>
<title>Lease Signed for New Distribution Centre</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/lease-signed-for-new-distribution-centre</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/lease-signed-for-new-distribution-centre</guid>
<pubDate>Thu, 05 Mar 2026 07:00:00 GMT</pubDate>
<description>Vulcan Two Group plc has secured a ten-year lease for a new 22,000 sq ft distribution centre in Leeds, a move expected to reduce warehousing and logistical costs and enhance service delivery times. This strategic acquisition follows a £40 million institutional placing announced on 26 February 2026, intended to fund the acquisition of three ePharmacy companies. The lease commences with an initial rent of approximately £68,000 for eight months, transitioning to approximately £200,000 per annum the</description>
</item>
<item>
<title>Schedule One - Vulcan Two Group PLC</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/schedule-one-vulcan-two-group-plc</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/schedule-one-vulcan-two-group-plc</guid>
<pubDate>Wed, 04 Mar 2026 08:00:00 GMT</pubDate>
<description>Vulcan Two Group plc is seeking admission to AIM, planning a buy-and-build strategy for the UK ePharmacy market. The company has conditionally agreed to acquire CloudRx Holdings Limited, Hyperdrug Pharmaceuticals Ltd, and Webmed Pharmacy Ltd for approximately £41.7 million, funded by a £40 million institutional placing. This constitutes a reverse takeover, subject to shareholder approval. The enlarged company will have an anticipated market capitalization of £54.6 million upon readmission on Mar</description>
</item>
<item>
<title>Posting of Admission Document</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/posting-of-admission-document</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/posting-of-admission-document</guid>
<pubDate>Fri, 27 Feb 2026 16:43:00 GMT</pubDate>
<description>Vulcan Two Group plc has confirmed that its Admission Document, detailing recent acquisitions and a placing, will be posted to shareholders today, February 27, 2026. This document includes a notice for a General Meeting scheduled for March 17, 2026, where shareholders will vote on resolutions recommended by the Board as being in the best interests of the company and its shareholders. Directors intend to vote in favour of these resolutions, representing approximately 22.3 per cent. of the existin</description>
</item>
<item>
<title>Proposed Placing and Acquisitions</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/proposed-placing-and-acquisitions-1</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/proposed-placing-and-acquisitions-1</guid>
<pubDate>Thu, 26 Feb 2026 16:54:00 GMT</pubDate>
<description>Vulcan Two Group plc is proposing to acquire three UK ePharmacy companies, CloudRx Holdings Limited, Hyperdrug Pharmaceuticals Ltd, and Webmed Pharmacy Ltd, for a total maximum consideration of approximately £41.7 million, with £37.1 million payable in cash. To fund this, the company plans to raise £40 million through an institutional placing of new ordinary shares at 200 pence per share. These acquisitions constitute a reverse takeover, requiring shareholder approval. The enlarged group is proj</description>
</item>
<item>
<title>Board Update</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/board-update-66</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/board-update-66</guid>
<pubDate>Mon, 12 Jan 2026 07:00:00 GMT</pubDate>
<description>Vulcan Two Group plc announced a board update, with CFO Simon Carter stepping down from his role for personal reasons but remaining with the company in a new finance team position. Keith Butcher, an experienced former CFO of LSE-listed companies, has been appointed as interim CFO for at least six months, with potential board appointment contingent on the company completing an acquisition. Additionally, Dr. David Wong has joined the board as a Non-Executive Director, bringing significant healthca</description>
</item>
<item>
<title>Directorate change</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/directorate-change-1079</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/directorate-change-1079</guid>
<pubDate>Thu, 13 Nov 2025 07:00:00 GMT</pubDate>
<description>Vulcan Two Group plc announced the appointment of Simon Carter as Chief Financial Officer and Director, effective immediately. Carter brings over 20 years of finance experience, including his prior role as Finance Lead at EssilorLuxottica SA's UK Contact Lens Hub following their acquisition of Vision Direct, where he managed budgeting, forecasting, planning, and reporting across various business units and countries. The company's CEO expressed confidence that Carter's expertise in the eCommerce </description>
</item>
<item>
<title>Interim Results</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/interim-results-708</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/interim-results-708</guid>
<pubDate>Tue, 23 Sep 2025 06:00:00 GMT</pubDate>
<description>Vulcan Two Group PLC reported the unaudited interim financial statements for the six months ended June 30, 2025, marking their first reporting period since admission to AIM, raising £12.0 million. The company's loss after taxation for the period was £79,892, compared to a loss of £15,437 in the same period of 2024. The company earned no revenue during this period. The cash balance at the period end was £4,669, a significant increase from £98 at the end of 2024. Administrative expenses totaled £7</description>
</item>
<item>
<title>Admission to AIM and First Day of Dealings</title>
<link>https://6ix.com/company/vulcan-two-group-plc/news/admission-to-aim-and-first-day-of-dealings-59</link>
<guid isPermaLink="true">https://6ix.com/company/vulcan-two-group-plc/news/admission-to-aim-and-first-day-of-dealings-59</guid>
<pubDate>Wed, 03 Sep 2025 06:00:00 GMT</pubDate>
<description>Vulcan Two Group PLC announced its admission to the AIM market of the London Stock Exchange with dealings commencing today under the ticker "VUL". The company's entire issued ordinary share capital consists of 6,775,000 ordinary shares of 10 pence each. In connection with the admission, Vulcan Two successfully raised £12.0 million through an institutional placing and direct subscription of 6,000,000 new ordinary shares at an issue price of 200 pence per share. The placing generated gross proceed</description>
</item>
</channel>
</rss>